Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Should l Buy ?
Source: Newsfilter
Financial Performance Overview: Claritev Corporation reported Q4 2024 revenues of $232.1 million with a net loss of $138.0 million, while the full year revenues totaled $930.6 million and a significant net loss of $1,645.8 million. Adjusted EBITDA for the year was $576.7 million.
Future Guidance and Strategy: For FY 2025, Claritev anticipates revenue to remain flat or decrease by 2% compared to FY 2024, with an adjusted EBITDA margin guidance of 62.5% to 63.5%. The company is focused on enhancing its healthcare technology solutions and executing its Vision 2030 plan following a successful debt refinancing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
